Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Determination 2021
made under subsection 23B(10) of the
Therapeutic Goods Act 1989
Compilation No. 1
Compilation date: 1 April 2025
Includes amendments: F2025L00328
About this compilation
This compilation
This is a compilation of the Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Determination 2021 that shows the text of the law as amended and in force on 1 April 2025 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name
3 Authority
4 Definitions
5 Application
6 Form of information
7 Application, savings and transitional provisions
Schedule 1—Prescription Medicines
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
1 Name
This instrument is the Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Determination 2021.
3 Authority
This instrument is made under subsection 23B(10) of the Therapeutic Goods Act 1989.
4 Definitions
Note: A number of expressions used in this instrument are defined in subsection 3(1) of the Act, including the following:
(a) biological;
(b) medicine;
(c) Register;
(d) registered goods.
In this instrument:
Act means the Therapeutic Goods Act 1989.
biosimilar means a medicine that is a biosimilar in relation to a registered medicine.
eCTD means the electronic Common Technical Document standard format, including:
(a) Module 1 in accordance with eCTD AU module 1 and regional information v3.2, as in force or existing on 1 April 2025; and
(b) Modules 2 to 5 in accordance with ICH eCTD Specification v3.2.2, as in force or existing on 1 April 2025.
Note: The eCTD AU module 1 and regulation information v3.2 is published by the TGA on the TGA website at www.tga.gov.au. The ICH eCTD Specification v3.2.2. is published by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and is available at www.ich.org.
extension of indications medicine means a medicine that:
(a) contains the same chemical, biological or radiopharmaceutical active ingredient (or fixed combination of such ingredients) as another medicine included in the Register; and
(b) has one or more indications in addition to that other medicine.
generic product has the same meaning as in the Regulations.
major variation has the same meaning as in clause 1 of Schedule 9 to the Regulations.
major variation medicine means a medicine that is taken to be separate and distinct from a registered medicine because of a major variation but does not include:
(a) a new chemical entity medicine; or
(b) a new biological entity medicine; or
(c) a new biosimilar medicine; or
(d) a new combination medicine; or
(e) an extension of indications medicine; or
(f) a new generic medicine; or
(g) a new trade name medicine.
new biological entity medicine means a medicine that:
(a) has not previously been included in the Register, and contains a biological substance; or
(b) contains a biological substance mentioned in paragraph (c) of the definition of new chemical entity.
new biosimilar medicine means a medicine that has not previously been included in the Register and is a biosimilar in relation to a registered medicine.
new chemical entity has the same meaning as in clause 1 of Part 1 of Schedule 9 to the Regulations.
new chemical entity medicine means a medicine that contains a new chemical entity as mentioned in paragraphs (a), (b) and (d) of the definition of new chemical entity.
new combination medicine means a medicine that contains a new chemical entity as mentioned in paragraph (e) of the definition of new chemical entity.
new generic medicine means a medicine that has not previously been included in the Register and is a generic product.
new trade name medicine means a medicine that:
(a) has the same active ingredient or active ingredients (or fixed combination of active ingredients) as a registered medicine; and
(b) has the same indications as that other medicine; and
(c) has the same dosage form as that other medicine; and
(d) has been given a different name to that other medicine by the manufacturer, under which the medicine will be supplied.
registered medicine means a medicine that is included in the part of the Register for goods known as registered goods.
Regulations means the Therapeutic Goods Regulations 1990.
Therapeutic Goods Administration has the same meaning as in the Regulations.
5 Application
This instrument applies to medicines of the class specified in paragraph 4(1)(a) of the Therapeutic Goods (Classes of Therapeutic Goods) Instrument 2018.
Note: The Therapeutic Goods (Classes of Therapeutic Goods) Instrument 2018 is a notifiable instrument and is published on the Federal Register of Legislation at www.legislation.gov.au.
6 Form of information
For the purposes of subparagraph 23B(2)(d)(ii) of the Act, the information in an application dossier, that accompanies an application for the registration of a medicine mentioned in Schedule 1, must be in:
(a) the eCTD format; or
(b) if exceptional circumstances exist—another format with the prior written agreement of the Therapeutic Goods Administration.
7 Application, savings and transitional provisions
This instrument, as in force immediately before the amendments made by the Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Amendment Determination 2025, continues to apply to applications for registration made before 1 October 2025.
Schedule 1—Prescription Medicines
Note: See section 6.
Prescription medicines | |
Column 1 | Column 2 |
Item | Prescription medicines |
1 | new chemical entity medicine |
2 | new biological entity medicine |
3 | new biosimilar medicine |
4 | new combination medicine |
5 | extension of indications medicine |
6 | major variation medicine |
7 | new generic medicine |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.
If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.
Endnote 2—Abbreviation key
ad = added or inserted | orig = original |
am = amended | par = paragraph(s)/subparagraph(s) |
amdt = amendment | /sub‑subparagraph(s) |
c = clause(s) | pres = present |
C[x] = Compilation No. x | prev = previous |
Ch = Chapter(s) | (prev…) = previously |
def = definition(s) | Pt = Part(s) |
Dict = Dictionary | r = regulation(s)/rule(s) |
disallowed = disallowed by Parliament | reloc = relocated |
Div = Division(s) | renum = renumbered |
exp = expires/expired or ceases/ceased to have | rep = repealed |
effect | rs = repealed and substituted |
F = Federal Register of Legislation | s = section(s)/subsection(s) |
gaz = gazette | Sch = Schedule(s) |
LA = Legislation Act 2003 | Sdiv = Subdivision(s) |
LIA = Legislative Instruments Act 2003 | SLI = Select Legislative Instrument |
(md not incorp) = misdescribed amendment | SR = Statutory Rules |
cannot be given effect | Sub‑Ch = Sub‑Chapter(s) |
mod = modified/modification | SubPt = Subpart(s) |
No. = Number(s) | underlining = whole or part not |
o = order(s) | commenced or to be commenced |
Ord = Ordinance |
|
Endnote 3—Legislation history
Name | Registration | Commencement | Application, saving and transitional provisions |
Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Determination 2021 | 28 Oct 2021 (F2021L01466) | s 1-7 and Sch 1 (items 1-4): 1 Nov 2021 (s 2(1) items 1, 2) Sch 1 (items 5-7): 1 June 2022 (s 2(1) item 3) | — |
Therapeutic Goods (Prescription Medicines—Information Accompanying Applications for Registration) Amendment Determination 2025 | 11 Mar 2025 (F2025L00328) | 1 Apr 2025 | — |
Endnote 4—Amendment history
Provision affected | How affected |
s 2……………………………….. | rep LA s 48D |
s 4……………………………….. | am F2025L00328 |
s 7……………………………….. | ad F2025L00328 |